Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study
PR Newswire —
SAN FRANCISCO and SUZHOU, China, March 22, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic,...